NGM Biopharmaceuticals, Inc. NGM
Set alert
1.54 0.00 0.00%
At close · Apr 4
1.54 Day range 1.57
52-week range unavailable
- Open
- 1.56
- Prev close
- 1.54
- Mkt cap
- 128.53M
- Vol
- 2.21M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.54
- High
- 1.57
- Forward P/E
- -2.05
- Beta
- 1.26
- Short ratio
- 1.26
- Inst. own
- 54.16%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 2, 2024
- 50-d avg
- 1.55
- 200-d avg
- 1.47
- 1y target
- 1.66
Analyst view
Consensus: hold
Hold
Price target (mean) 1.66 +7.8% upside
Now 1.54
- Target (low)
- 1.55
- Target (mean)
- 1.66
- Target (high)
- 2.00
Ratings (-1m) 6 4 buy · 2 hold · 0 sell
- Strong buy1
- Buy3
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.46 | -0.46 – -0.46 | -0.58 | +20.7% | 0 | 0.0% | 1 |
| Next quarter | -0.29 | -0.29 – -0.29 | -0.46 | +37.0% | 0 | 0.0% | 1 |
| Current year | -1.32 | -1.32 – -1.32 | -1.73 | +23.7% | 0 | 0.0% | 1 |
| Next year | -0.75 | -0.75 – -0.75 | -1.32 | +43.2% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 2, 2023 | Citigroup | Initiated | — | Buy |
| Mar 29, 2023 | B. Riley Securities | Maintained | — | Buy |
| Nov 3, 2022 | Raymond James | Maintained | — | Outperform |
| Oct 17, 2022 | Cowen & Co. | Maintained | — | Outperform |
| Oct 17, 2022 | Goldman Sachs | Downgrade | Buy | Neutral |
| Oct 17, 2022 | Raymond James | Downgrade | Strong Buy | Outperform |
| Oct 16, 2022 | Jefferies | Downgrade | Buy | Hold |
| Oct 16, 2022 | Piper Sandler | Downgrade | Overweight | Neutral |
| Oct 6, 2022 | B. Riley Securities | Maintained | — | Buy |
| Jul 19, 2022 | Jefferies | Initiated | — | Buy |
| May 23, 2022 | Goldman Sachs | Maintained | — | Buy |
| Nov 4, 2021 | Raymond James | Maintained | — | Strong Buy |
| Sep 16, 2021 | BMO Capital | Maintained | — | Outperform |
| Sep 12, 2021 | Raymond James | Upgrade | Outperform | Strong Buy |
| Aug 5, 2021 | Raymond James | Maintained | — | Outperform |
| May 23, 2021 | Raymond James | Downgrade | Strong Buy | Outperform |
| Mar 4, 2021 | Chardan Capital | Maintained | — | Buy |
| Mar 4, 2021 | Raymond James | Maintained | — | Strong Buy |
| Jan 7, 2021 | Raymond James | Maintained | — | Strong Buy |
| Aug 12, 2020 | Chardan Capital | Maintained | — | Buy |
| Jul 30, 2020 | Piper Sandler | Initiated | — | Overweight |
| Jul 6, 2020 | Chardan Capital | Initiated | — | Buy |
| Jun 4, 2020 | BMO Capital | Initiated | — | Outperform |
| May 13, 2020 | Raymond James | Maintained | — | Strong Buy |
| Apr 6, 2020 | Raymond James | Initiated | — | Strong Buy |
| Mar 26, 2020 | Citigroup | Maintained | — | Buy |
| Mar 18, 2020 | Stifel | Maintained | — | Buy |
| Feb 25, 2020 | B. Riley Securities | Maintained | — | Buy |
| Feb 24, 2020 | Stifel | Maintained | — | Buy |
| Oct 16, 2019 | B. Riley Securities | Initiated | — | Buy |